Apellis Pharmaceuticals
1D
1W
1M
3M
YTD
1Y
5Y
ALL
Why Robinhood?
Robinhood gives you the tools you need to put your money in motion. You can buy or sell APLS and other ETFs, options, and stocks.About APLS
Apellis Pharmaceuticals, Inc. is a commercial-stage biopharmaceutical company, which engages in the discovery, development, and commercialization of novel therapeutic compounds to treat diseases with high unmet needs. Its products include EMPAVELI and SYFOVRE.
CEOCedric Francois
CEOCedric Francois
Employees710
Employees710
HeadquartersWaltham, Massachusetts
HeadquartersWaltham, Massachusetts
Founded2009
Founded2009
Employees710
Employees710
APLS Key Statistics
Market cap2.29B
Market cap2.29B
Price-Earnings ratio-10.18
Price-Earnings ratio-10.18
Dividend yield—
Dividend yield—
Average volume2.01M
Average volume2.01M
High today$18.27
High today$18.27
Low today$17.73
Low today$17.73
Open price$18.00
Open price$18.00
Volume891.08K
Volume891.08K
52 Week high$42.47
52 Week high$42.47
52 Week low$16.10
52 Week low$16.10
APLS News
TipRanks 3d
Cautious Optimism: Apellis Pharmaceuticals’ Strategic Moves and Market Uncertainties Justify Hold RatingAnalyst Judah Frommer from Morgan Stanley maintained a Hold rating on Apellis Pharmaceuticals (APLS – Research Report) and increased the price target to $26.00...
Analyst ratings
59%
of 22 ratingsBuy
59.1%
Hold
40.9%
Sell
0%
People also own
Based on the portfolios of people who own APLS. This list is generated using Robinhood data, and it’s not a recommendation.